Ibrahim B. Dagher insider trades: Brainstorm Cell Therapeutics (BCLI) stock sales
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where Ibrahim reports to the SEC
Open-market buys and sales
1 trade reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Jul 19, 2024 | BCLI | ↓ Sell | 63,000 | $0.35 | $22K | Direct | Jul 24, 2024 (5d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
About Ibrahim B. Dagher's insider trades
Ibrahim B. Dagher is a director at Brainstorm Cell Therapeutics (BCLI). Since Jul 19, 2024, Ibrahim has reported no open-market purchases and 1 sale worth $22K on SEC Form 4. There have been no open-market trades in the last 12 months.
Their filings also include grants and awards (2 filings). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every BCLI insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.